Menu
Innovation Observatory > Reports > Drugs > Galcanezumab for the prophylaxis of episodic and chronic migraine

< Back

Galcanezumab for the prophylaxis of episodic and chronic migraine

Drugs

Neurology and Neurosurgery

October 2017


Galcanezumab is being developed as one of a class of specific anti-migraine preventative drugs. By stopping a very specific protein in the brain and nervous system, galcanezumab reduces migraine attacks. Additionally as it is given once-a-month as treatment, it avoids the need to take numerous pills per day. If marketed, galcanezumab may be more preferable to current treatment options for episodic migraine and chronic migraine prevention.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Connect to the Innovation Observatory

Twitter

 

Related Information



Load More Related Posts
Get Alerts